Shares of marijuana producer Tilray (NASDAQ:TLRY) jumped in Monday’s (June 10) trading session following a special arrangement with its biggest investor to place restrictions on its shares.

According to Tilray, the special agreement with Privateer Holdings will extend the current lockup of 75 million shares of the marijuana company, so if a sale of shares happens it will be heavily restricted.

Tilray opened on Monday at a price of US$44.26. The stock finished the day with an increase of 14.88 percent from the previous day’s close to reach a price point of US$44.57.

In this transaction, Tilray will acquire Privateer in what is referred to as a downstream merger. Once the acquisition goes through, Tilray will issue Privateer shareholders the same number of its own shares that they currently own.

The resulting new shares will be placed in a lockup and only allowed for sale in special conditions over a two year period.

During the first year, the restriction will be held except for “marketed offerings and/or block trades to institutional investors or via stock sales to strategic investors.”

Privateer financed Tilray’s early days and its path to its initial public offering (IPO) on a senior US exchange in July 2018. Brendan Kennedy, CEO of Tilray, acts as executive chairman for the investment firm as well.

In May, Bloomberg issued a list of the highest-paid executives, with Kennedy securing the second position, fueled in part by the company’s meteoric rise in the stock market.

“We believe this transaction will give Tilray greater control and operating flexibility, while allowing us to effectively manage our public float,” Mark Castaneda, chief financial officer of Tilray, said in a press release.

Seattle-based investment firm Privateer holds an ownership stake of 77 percent of Tilray’s total outstanding shares.

Michael Blue, managing partner of Privateer, said the investment firm sees this deal as maximizing overall returns for its investors, while at the same time giving Tilray “the operating flexibility it needs” in its operations.

In January, Tilray reached the IPO lockup deadline for its shares, which caused the stock to drop double digits in value.

The stock of Tilray is removed from its volatile trading days during which it was a popular trading item that even reached a price of US$300 at one time in 2018.

Over a year-to-date period the company has posted a loss in value of 44.93 percent. However, since the IPO was completed in July 2018, the company has surged 30.33 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less